Mene Pangalos (AstraZeneca via YouTube)
September 23, 2022 07:29 AM EDT
R&D

As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

Amber Tong

When Io­n­is and As­traZeneca un­veiled the first round of mid-stage da­ta for their an­ti­sense PC­SK9 drug, Mene Pan­ga­los, As­traZeneca’s EVP of bio­phar­ma­ceu­ti­cals R&D, un­der­scored the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times